Imbruvica (Ibrutinib) - Drug Insight and Market Forecast - 2030

Overview

Imbruvica (ibrutinib) - Drug Insight and Market Forecast - 2030 report by the publisher outlays comprehensive insights of the product indicated for the treatment of its approved condition. A detailed picture of the Imbruvica (ibrutinib) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2017-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details, regulatory milestones, and other development activities. Further, it also consists of market assessments inclusive of the market forecast, SWOT analysis, and detailed analyst views. It further highlights the market competitors, late-stage emerging therapies, and patent details in the global space.

Imbruvica (ibrutinib) is a once-daily oral medicine that works differently than chemotherapy as it blocks the Bruton's tyrosine kinase (BTK) protein. The BTK protein sends important signals that tell B cells to mature and produce antibodies. BTK signaling is needed by specific cancer cells to multiply and spread.2,3 By blocking BTK, Imbruvica may help move abnormal B cells out of their nourishing environments in the lymph nodes, bone marrow, and other organs. Imbruvica is approved in more than 90 countries, and, to date, has been used to treat more than 135,000 patients worldwide across approved indications. It was first approved by the US Food and Drug Administration (FDA) in November 2013, and is indicated in six disease areas, including five hematologic cancers - chronic lymphocytic leukemia (CLL) with or without 17p deletion (del17p), small lymphocytic lymphoma (SLL) with or without del17p, Waldenström's macroglobulinemia (WM), previously-treated patients with mantle cell lymphoma (MCL), previously-treated patients with marginal zone lymphoma (MZL) who require systemic therapy and have received at least one prior anti-CD20-based therapy - and previously-treated patients with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy. Imbruvica is the first and only FDA-approved medicine in WM, MZL* and cGVHD. IMBRUVICA has been granted four Breakthrough Therapy Designations by the FDA, and it was one of the first medicines to receive US approval through the Breakthrough Therapy Designation.

Scope of the report

The report provides insights into:

• A comprehensive product overview including the product description, mechanism of action, dosage and administration, route of synthesis, pharmacological studies (pharmacodynamics and pharmacokinetics) and adverse reactions.
• Elaborated details on regulatory milestones and other development activities have been provided in this report.
• The report also highlights the drug marketed details across the United States, Europe and Japan.
• The report also covers the patent's information with expiry timeline around Imbruvica (ibrutinib).
• The report contains historical and forecasted sales for Imbruvica (ibrutinib) till 2030.
• Comprehensive coverage of the late-stage emerging therapies (Phase III) in the space with a brief snapshot of the details.
• The report also features the SWOT analysis with analyst insights and key findings of Imbruvica (ibrutinib).

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the publisher's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Imbruvica (ibrutinib) Analytical Perspective

In-depth Imbruvica (ibrutinib) Market Assessment

This report provides a detailed market assessment of Imbruvica (ibrutinib) in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides historical and forecasted sales data from 2017 to 2030.

Imbruvica (ibrutinib) Clinical Assessment

The report provides the clinical trials information of Imbruvica (ibrutinib) covering trial interventions, trial conditions, trial status, start and completion dates.

Report highlights

• In the coming years, the market scenario for Imbruvica (ibrutinib) is set to change due to the extensive research in the treatment of the indicated condition and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Imbruvica (ibrutinib) dominance. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Other approved products for the disease are giving market competition to Imbruvica (ibrutinib) and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, development activities, and some key findings provide the current market scenario of Imbruvica (ibrutinib).
• Our in-depth analysis of the sales data of Imbruvica (ibrutinib) from 2017 to 2030 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Imbruvica (ibrutinib) in the market.

Key Questions Answered

• What is the prescribed dosage and strengths of Imbruvica (ibrutinib) are available in the market?
• What are the common adverse reactions or side effects of Imbruvica (ibrutinib)?
• What is the product type, route of administration and mechanism of action of Imbruvica (ibrutinib)?
• What are the chemical specifications of Imbruvica (ibrutinib)?
• How are the clinical trials diversified on the basis of the trial status?
• What is the history of Imbruvica (ibrutinib), and what is its future?
• What are the marketed details of Imbruvica (ibrutinib) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• How many patents have been granted to Imbruvica (ibrutinib) and when these patents will get expire?
• What are the pros (benefits) and cons (disadvantages) of Imbruvica (ibrutinib)?
• In which countries Imbruvica (ibrutinib) got approval and when it gets launched?
• What are the clinical trials are currently ongoing for Imbruvica (ibrutinib)?
• How the safety and efficacy results determined the approval of Imbruvica (ibrutinib)?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Imbruvica (ibrutinib) development?
• What are the key designations that have been granted to Imbruvica (ibrutinib)?
• What is the historical and forecasted market scenario of Imbruvica (ibrutinib)?
• How is the market trend of Imbruvica (ibrutinib) is different in the Seven Major Markets (the United States, EU5 [Germany, France, Italy, Spain, and the United Kingdom], and Japan)?
• What are the other approved products available and how these are giving competition to Imbruvica (ibrutinib)?
• Which are the late-stage emerging therapies under development for the treatment of the indicated condition?